One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Prediction of sudden death in the era of personalized medicine
Filippo Crea
doi : 10.1093/eurheartj/ehab215
Volume 42, Issue 17, 1 May 2021, Pages 1641–1644,
Joint editors unveiled for CardioPulse
Mark Nicholls
doi : 10.1093/eurheartj/ehab129
Volume 42, Issue 17, 1 May 2021, Pages 1645–1653,
The Year in Cardiovascular Medicine 2020: Imaging
Judith Ozkan
doi : 10.1093/eurheartj/ehaa1036
Volume 42, Issue 17, 1 May 2021, Pages 1646–1648,
Dr John Joseph Gallagher (1943–2020)
Richard Hauer
doi : 10.1093/eurheartj/ehab049
Volume 42, Issue 17, 1 May 2021, Pages 1648–1650,
The Birth of Cardiology: The Golden Decade
Eugene Braunwald
doi : 10.1093/eurheartj/ehab119
Volume 42, Issue 17, 1 May 2021, Pages 1650–1651,
GLP-1 receptor agonists: fighting obesity with an eye to cardiovascular risk
Giovanna Liuzzo, Leonarda Galiuto
doi : 10.1093/eurheartj/ehab175
Volume 42, Issue 17, 1 May 2021, Pages 1652–1653,
Tilt testing remains a valuable asset
Richard Sutton, Artur Fedorowski, Brian Olshansky, J Gert van Dijk, Haruhiko Abe
doi : 10.1093/eurheartj/ehab084
Volume 42, Issue 17, 1 May 2021, Pages 1654–1660,
Head-up tilt test (TT) has been used for >50?years to study heart rate/blood pressure adaptation to positional changes, to model responses to haemorrhage, to assess orthostatic hypotension, and to evaluate haemodynamic and neuroendocrine responses in congestive heart failure, autonomic dysfunction, and hypertension. During these studies, some subjects experienced syncope due to vasovagal reflex.
Precision Medicine and cardiac channelopathies: when dreams meet reality
Massimiliano Gnecchi, Luca Sala, Peter J Schwartz
doi : 10.1093/eurheartj/ehab007
Volume 42, Issue 17, 1 May 2021, Pages 1661–1675,
Precision Medicine (PM) is an innovative approach that, by relying on large populations’ datasets, patients’ genetics and characteristics, and advanced technologies, aims at improving risk stratification and at identifying patient-specific management through targeted diagnostic and therapeutic strategies. Cardiac channelopathies are being progressively involved in the evolution brought by PM and some of them are benefiting from these novel approaches, especially the long QT syndrome. Here, we have explored the main layers that should be considered when developing a PM approach for cardiac channelopathies, with a focus on modern in vitro strategies based on patient-specific human-induced pluripotent stem cells and on in silico models.
Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score
Arwa Younis, Jeffrey J Goldberger, Valentina Kutyifa, Wojciech Zareba, Bronislava Polonsky
doi : 10.1093/eurheartj/ehaa1057
Volume 42, Issue 17, 1 May 2021, Pages 1676–1684,
The benefit of prophylactic implantable cardioverter-defibrillator (ICD) is not uniform due to differences in the risk of life-threatening ventricular tachycardia (VT)/ventricular fibrillation (VF) and non-arrhythmic mortality. We aimed to develop an ICD benefit prediction score that integrates the competing risks.
Precision prevention with ICDs: can a simple score improve patient selection?
David R Okada, Hugh Calkins
doi : 10.1093/eurheartj/ehaa1102
Volume 42, Issue 17, 1 May 2021, Pages 1685–1686,
Robustness and relevance of predictive score in sudden cardiac death for patients with Brugada syndrome
Vincent Probst, Thomas Goronflot, Soraya Anys, Romain Tixier, Jean Briand
doi : 10.1093/eurheartj/ehaa763
Volume 42, Issue 17, 1 May 2021, Pages 1687–1695,
Risk stratification of sudden cardiac arrest (SCA) in Brugada syndrome (Brs) remains the main challenge for physicians. Several scores have been suggested to improve risk stratification but never replicated. We aim to investigate the accuracy of the Brs risk scores.
Risk stratification in Brugada syndrome: the challenge of the grey zone
Pietro Delise
doi : 10.1093/eurheartj/ehaa1100
Volume 42, Issue 17, 1 May 2021, Pages 1696–1697,
Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial
Kazuma Oyama, Robert P Giugliano, David D Berg, Christian T Ruff, Petr Jarolim
doi : 10.1093/eurheartj/ehab141
Volume 42, Issue 17, 1 May 2021, Pages 1698–1706,
We investigated whether patients with atrial fibrillation (AF) demonstrate detectable changes in biomarkers including high-sensitivity troponin T (hsTnT), N-terminal B-type natriuretic peptide (NT-proBNP), and growth differentiation factor-15 (GDF-15) over 12?months and whether such changes from baseline to 12?months are associated with the subsequent risk of stroke or systemic embolic events (S/SEE) and bleeding.
What do we learn by repeating the ABC?
Marvin Krohn-Grimberghe, Daniel Duerschmied, Christoph Bode
doi : 10.1093/eurheartj/ehab146
Volume 42, Issue 17, 1 May 2021, Pages 1707–1709,
Effectiveness of Closed Loop Stimulation pacing in patients with cardio-inhibitory vasovagal reflex syncope is questionable
Wouter Wieling, David L Jardine
doi : 10.1093/eurheartj/ehab157
Volume 42, Issue 17, 1 May 2021, Page 1710,
Are convictions more dangerous enemies of truth than lies?
Michele Brignole, Richard Sutton, Artur Fedorowski
doi : 10.1093/eurheartj/ehab164
Volume 42, Issue 17, 1 May 2021, Pages 1711–1712,
Unconventional treatment of infectious device protrusion after elective pacemaker generator exchange: part II
Tardu ?zkartal, Marcello Di Valentino, Andrea Menafoglio
doi : 10.1093/eurheartj/ehaa687
Volume 42, Issue 17, 1 May 2021, Page 1713,
Left ventricular diverticulum associated with two concealed atrioventricular accessory pathways
Damien Minois, Jean Marc Sellal, Isabelle Magnin, Christian de Chillou
doi : 10.1093/eurheartj/ehaa851
Volume 42, Issue 17, 1 May 2021, Page 1714,
